Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals
A snapshot of the stocks on the move, featuring PainChek (ASX:PCK), Chimeric Therapeutics (ASX:CHM) and Torque Metals (ASX:TOR).
Watch Now
Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.
The Company believes that cellular therapies have the promise to cure cancer, not just delay disease progression. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.
ASX Code
CHM
A snapshot of the stocks on the move, featuring PainChek (ASX:PCK), Chimeric Therapeutics (ASX:CHM) and Torque Metals (ASX:TOR).
Watch Now
Jennifer Chow - CEO & Managing Director - Chimeric Therapeutics (ASX:CHM) is a clinical-stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Watch Now
A snapshot of the stocks on the move, featuring QX Resources (ASX:QXR), Chimeric Therapeutics (ASX:CHM) and Alliance Nickel (ASX:AXN).
Watch Now
A snapshot of the stocks on the move, featuring Chimeric Therapeutics (ASX:CHM), Armada (ASX:AMM), Site Group International (ASX:SIT) and Linius Technologies (ASX:LNU).
Watch Now
A snapshot of the stocks on the move, featuring Origin Energy (ASX:ORG), Sunstone Metals (ASX:STM) and Chimeric Therapeutics (ASX:CHM).
Watch Now
Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy, CHM 1301. These preclinical results highlight the therapy's notable efficacy against ovarian and pancreatic cancers, suggesting potential advancements in cancer treatment.
Read More
The price of gold has dropped to a five-month low due to improved expectations of a gentle economic slowdown in the US and a series of disappointing economic indicators from China.
Read More